multiple-myeloma

Documents about multiple-myeloma

• Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function#869844ClinicalTrials.gov
• Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes#837316ClinicalTrials.gov
• Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology#876392ClinicalTrials.gov
• Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)#889910ClinicalTrials.gov
• Study of INCB053914 in Subjects With Advanced Malignancies#914746ClinicalTrials.gov
• Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma#869191ClinicalTrials.gov
• Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial#296802Gestión del Repositorio Documental de la Universidad de Salamanca
• The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM#121829HAL (France)
• A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)#839125ClinicalTrials.gov
• The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia#859301ClinicalTrials.gov
• Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients#901004ClinicalTrials.gov
• Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant#968687ClinicalTrials.gov
• Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant#651118ClinicalTrials.gov
• Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies#835158ClinicalTrials.gov
• To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL#852394ClinicalTrials.gov
• Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification#982262ClinicalTrials.gov
• Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer#172325ClinicalTrials.gov
• Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results#174819PLOS
• Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance#294455Gestión del Repositorio Documental de la Universidad de Salamanca
• Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7#299087Springer Nature OA
• Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence#843616ClinicalTrials.gov
• Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation#967137ClinicalTrials.gov
• Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies#836103ClinicalTrials.gov
• A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies#851055ClinicalTrials.gov
• FAPI PET Imaging - An Exploratory Study#870195ClinicalTrials.gov
• Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation#906296ClinicalTrials.gov
• Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies#802647ClinicalTrials.gov
• Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)#845597ClinicalTrials.gov
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)#861735ClinicalTrials.gov
• MargheRITA (Remote Intelligence for Therapeutic Adherence)#886424ClinicalTrials.gov
• Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients#840734ClinicalTrials.gov
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium#863870ClinicalTrials.gov
• Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy#889566ClinicalTrials.gov
• Advances in estimating plasma cells in bone marrow : a comprehensive method review#293178SUNScholar
• Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation#800296ClinicalTrials.gov
• Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide#833873ClinicalTrials.gov
• Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain#877729ClinicalTrials.gov
• Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)#905070ClinicalTrials.gov
• Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma#609399eScholarship
• Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults#861752ClinicalTrials.gov
• Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells#982057ClinicalTrials.gov
• Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma#492101eScholarship
• Study of CAR-T Therapy in Older Patients#858191ClinicalTrials.gov
• Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases#873076ClinicalTrials.gov
• Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders#831931ClinicalTrials.gov
• Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event#857835ClinicalTrials.gov
• Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma / Henrik Niklas, Anna Bold, Simon Völkl, Nicola Lang, Marietta Truger, Knut Wendelin, Susanne Strifler, Johannes Gärtner, Stefan Knop#983100Deutsche Nationalbibliothek
• Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies#838611ClinicalTrials.gov
• Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies#845424ClinicalTrials.gov
• Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies#888432ClinicalTrials.gov